. >> reporter: merck says ituote continues to work around the clock to get bcg to as many patients as we can and itma s firmly committed to patients and physicians where otr companies have chosen to exit the market and no others have chosen to invest in manufacturing. it cts $170 per vial and patients get six via over six weeks. some question whether a higher price could address the problem, somethingmerck's ceo discussed. >> by raising the price could you manufacture more? supply the whole market if you raised the price? >> i think this is the emplar of a big problem that's going to continue going forward. when the prices of drugs get too low, particularly generic drugs, thenarou don't havet incentive for people to t capital up to build facilities like we need for additional amounts. for merck the challenge h is can we maximize the amount we can make for patients given the fact that the other two companies have droppedar out of thet in the moral of the story is sometimes drugs are not available because the prices are are t high. because the prices >> reporter: merck's cancer drug key